FI945556A - Tulehdustenvastaiset 3-aryyli-2-isoksatsoliinijohdannaiset - Google Patents

Tulehdustenvastaiset 3-aryyli-2-isoksatsoliinijohdannaiset Download PDF

Info

Publication number
FI945556A
FI945556A FI945556A FI945556A FI945556A FI 945556 A FI945556 A FI 945556A FI 945556 A FI945556 A FI 945556A FI 945556 A FI945556 A FI 945556A FI 945556 A FI945556 A FI 945556A
Authority
FI
Finland
Prior art keywords
pct
aryl
date
sec
inflammatory
Prior art date
Application number
FI945556A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI945556A0 (fi
Inventor
Edward F Kleinman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI945556A0 publication Critical patent/FI945556A0/fi
Publication of FI945556A publication Critical patent/FI945556A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FI945556A 1993-11-26 1994-11-25 Tulehdustenvastaiset 3-aryyli-2-isoksatsoliinijohdannaiset FI945556A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15724193A 1993-11-26 1993-11-26

Publications (2)

Publication Number Publication Date
FI945556A0 FI945556A0 (fi) 1994-11-25
FI945556A true FI945556A (fi) 1995-05-27

Family

ID=22562909

Family Applications (1)

Application Number Title Priority Date Filing Date
FI945556A FI945556A (fi) 1993-11-26 1994-11-25 Tulehdustenvastaiset 3-aryyli-2-isoksatsoliinijohdannaiset

Country Status (12)

Country Link
US (1) US5686434A (el)
EP (1) EP0730587B1 (el)
JP (1) JP2818820B2 (el)
AT (1) ATE187447T1 (el)
CA (1) CA2177375A1 (el)
DE (1) DE69422061T2 (el)
DK (1) DK0730587T3 (el)
ES (1) ES2139754T3 (el)
FI (1) FI945556A (el)
GR (1) GR3032506T3 (el)
PT (1) PT730587E (el)
WO (1) WO1995014680A1 (el)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0920421B1 (en) * 1996-08-21 2002-11-06 PHARMACIA & UPJOHN COMPANY Isoxazoline derivatives useful as antimicrobials
JP2001503443A (ja) * 1996-11-11 2001-03-13 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 新規イミダゾ―及びオキサゾロピリジン
DE59808163D1 (de) * 1997-01-17 2003-06-05 Basf Ag Verfahren zur herstellung von schwefelhaltigen 2-chlor-3-(4,5-dihydroisoxazol-3-yl)-benzoesäuren
US6022977A (en) 1997-03-26 2000-02-08 Dupont Pharmaceuticals Company Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
ATE222894T1 (de) * 1998-02-13 2002-09-15 Upjohn Co Substituierte aminophenylisoxazolinderivate verwendbar als antimikrobielle agenzien
DE19852095A1 (de) 1998-11-12 2000-05-18 Basf Ag Verfahren zur Herstellung von 2-Alkyl-3-(4,5-dihydroisoxazol-3-yl)-acylbenzolen
CA2331816C (en) * 1998-05-11 2010-11-16 Basf Aktiengesellschaft Method for producing isoxazoline-3-yl-acyl benzene
AU763460B2 (en) * 1998-10-09 2003-07-24 Janssen Pharmaceutica N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
CA2381802C (en) 1999-08-21 2010-12-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of roflumilast and salmeterol
CA2388564C (en) * 1999-09-17 2007-11-06 Lg Chem Investment Ltd. Caspase inhibitor
KR100399361B1 (ko) 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
DE19953024A1 (de) * 1999-11-04 2001-05-10 Merck Patent Gmbh Isoxazolderivate als Phosphodiesterase VII-Hemmer
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EA200501548A1 (ru) 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Ингибиторы фосфодиэстераз при бесплодии
KR100594544B1 (ko) 2003-08-27 2006-06-30 주식회사 엘지생명과학 이소옥사졸린 구조를 갖는 캐스파제 저해제
BRPI0413330A (pt) * 2003-08-29 2006-10-10 Ranbaxy Lab Ltd inibidores de fosfodiesterase do tipo iv, composição farmacêutica contendo os mesmos e processo para sua preparação
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
CA2557166C (en) * 2004-03-26 2015-06-30 Cytokine Pharmasciences, Inc. Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
AU2005265131B2 (en) * 2004-06-17 2012-02-23 Infinity Discovery, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
ES2370788T3 (es) * 2005-02-07 2011-12-22 Aerocrine Ab Controlar flujo de aliento exhalado durante análisis.
WO2006097273A1 (en) * 2005-03-15 2006-09-21 Ganial Immunotherapeutics Inc. Compounds having immunomodulator activity
EP3827747A1 (en) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
WO2007045980A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
EP2063905B1 (en) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20110021473A1 (en) * 2006-09-22 2011-01-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
NZ616673A (en) 2009-02-20 2014-08-29 To Bbb Holding B V Glutathione-based drug delivery system
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
CN101781294B (zh) * 2010-03-10 2012-02-01 天津药物研究院 一类咪唑的衍生物、其制备方法和用途
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
DK2691379T3 (en) 2011-03-31 2017-02-13 Bayer Ip Gmbh HERBICID AND FUNGICID ACTIVE 3-PHENYLISOXAZOLINE-5-CARBOXAMIDES AND 3-PHENYLISOXAZOLIN-5-THIOAMIDES
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
IN2015DN01315A (el) * 2012-09-25 2015-07-03 Bayer Cropscience Ag
CA2885692C (en) * 2012-09-25 2018-05-22 Bayer Cropscience Ag Herbicidal and fungicidal 5-oxy-substituted 3-phenylisoxazoline-5-carboxamides and 5-oxy-substituted 3-phenylisoxazoline-5-thioamides
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
CN110799511B (zh) 2017-06-13 2023-09-01 拜耳公司 除草活性的四氢和二氢呋喃甲酰胺的3-苯基异噁唑啉-5-甲酰胺
BR122023020315A2 (pt) 2017-06-13 2023-12-12 Bayer Aktiengesellschaft 3-fenilisoxazolina-5-carboxamidas
WO2019034602A1 (de) 2017-08-17 2019-02-21 Bayer Aktiengesellschaft Herbizid wirksame 3-phenyl-5-trifluormethylisoxazolin-5-carboxamide von cyclopentylcarbonsäuren und -estern
EP3743411B1 (de) 2018-01-25 2022-12-21 Bayer Aktiengesellschaft Herbizid wirksame 3-phenylisoxazolin-5-carboxamide von cyclopentenylcarbonsäurederivaten
DK3937637T3 (da) 2019-03-12 2023-07-24 Bayer Ag Herbicidt virksomme 3-phenylisoxazolin-5-carboxamider af s-holdige cyclopentenylcarbonsyreestere
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
JPS62103070A (ja) * 1985-10-29 1987-05-13 Mitsui Toatsu Chem Inc イソオキサゾリン誘導体および植物生長調節剤
US4912120A (en) * 1986-03-14 1990-03-27 Syntex (U.S.A.) Inc. 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors
HU215433B (hu) * 1986-04-29 2000-05-28 Pfizer Inc. Eljárás új 2-oxo-5-fenil-pirimidin-származékok előállítására
IE59813B1 (en) * 1986-05-09 1994-04-06 Warner Lambert Co Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them
ZA872997B (en) * 1986-05-09 1988-12-28 Warner Lambert Co Novel styryl pyrazoles,isoxazoles and analogs thereof having activity as 5-lipoxygenase inhibitors,pharmaceutical compositions and methods of use therefor
DE3736113A1 (de) * 1987-10-26 1989-05-03 Hoechst Ag Arzneimittel, darin enthaltene phosphorhaltige 2-isoxazoline und isoxazole, sowie herstellungsverfahren fuer diese heterocyclischen verbindungen
US4933464A (en) * 1988-04-25 1990-06-12 W. R. Grace & Co.-Conn. Process for forming 3-phenylisoxazolines and 3-phenylisoxazoles
US4952700A (en) * 1988-04-25 1990-08-28 W.R. Grace & Co.-Conn. Preparation of isoxazolines and isoxazoles
CA2017383A1 (en) * 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
WO1991007177A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
GB9007762D0 (en) * 1990-04-05 1990-06-06 Beecham Group Plc Novel compounds
EP0451790A1 (de) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung
DE4026018A1 (de) * 1990-08-17 1992-02-20 Hoechst Ag Isoxazoline oder isothiazoline enthaltende pflanzenschuetzende mittel und neue isoxazoline und isothiazoline
AU9030691A (en) * 1990-11-06 1992-05-26 Smithkline Beecham Corporation Imidazolidinone compounds
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
AU2869092A (en) * 1991-10-11 1993-05-03 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production

Also Published As

Publication number Publication date
DE69422061D1 (de) 2000-01-13
CA2177375A1 (en) 1995-06-01
DK0730587T3 (da) 2000-04-10
EP0730587B1 (en) 1999-12-08
ATE187447T1 (de) 1999-12-15
DE69422061T2 (de) 2000-03-30
US5686434A (en) 1997-11-11
FI945556A0 (fi) 1994-11-25
EP0730587A1 (en) 1996-09-11
JP2818820B2 (ja) 1998-10-30
ES2139754T3 (es) 2000-02-16
WO1995014680A1 (en) 1995-06-01
JPH09500146A (ja) 1997-01-07
GR3032506T3 (en) 2000-05-31
PT730587E (pt) 2000-05-31

Similar Documents

Publication Publication Date Title
FI945556A (fi) Tulehdustenvastaiset 3-aryyli-2-isoksatsoliinijohdannaiset
FI945557A (fi) Isoksatsoliiniyhdisteet tulehduksenvastaisina aineina
FI945555A (fi) Substituoituja oksindoleja
DK0672031T3 (da) Catecholdiethere som selektive PDE IV-inhibitorer
ZA9810735B (en) Novel benzenesulfonamide inhibitors of pde-iv and their therapeutic use
DK0980374T3 (da) Phosphodiesterase 4-inhiberende diazepinoindoloner.
DK0752990T3 (da) Benzisothiazolderivater som inhibitorer af 5-lipoxygenasebiosyntese
ATE186528T1 (de) Indol-carbamate als leukotriene antagonisten
MX9603943A (es) Compuestos de isoxazolina como inhibidores de 5-lipooxigenasa.

Legal Events

Date Code Title Description
FD Application lapsed